• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Recall of Baxter Clearlink due to risk of leaks is Class I

September 15, 2022 By Sean Whooley

Baxter logoThe FDA announced today that the recall of the Clearlink basic solution set with Duovent from Baxter (NYSE:BAX) is Class I, the most serious kind.

Clearkink with Duovent is part of a system for administering drugs and solutions to patients. Health providers use the majority of the sets to deliver hazardous drugs, such as chemotherapy drugs.

Reason for recall

Increased customer reports of leaks led Baxter to recall the Clearlink set, since the leaks could expose people to hazardous drugs.

Leaks may also allow air into the set or breach the sterile fluid pathway. These incidents increase the risk of air embolism and contaminated infusions, respectively. This could result in delayed or interrupted therapy, meaning patients may not receive the necessary amount of medication.

Altogether, these issues could lead to serious injury or death, an FDA notice said. To date, Baxter received 83 complaints with no reported injuries or deaths associated with the issues.

Product details

Baxter recalled the Clearlink basic solution set with Duovent. The product code is 2R8403 (all lots within expiry).

The company distributed 511,728 devices in the U.S. between Oct. 14, 2020, and June 30, 2022. Baxter initiated the recall on Aug. 9, 2022.

Instructions for users of recalled products

Baxter’s urgent medical device recall letter instructed users to monitor the use of impacted solution sets closely for leaks. They should stop the use of affected products if leaks are experienced. Affected products can be returned to Baxter.

The company is implementing corrective actions to resolve the issue. It plans to send a follow-up notification to customers with additional instructions.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Recalls Tagged With: Baxter, FDA

IN CASE YOU MISSED IT

  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
  • Mosanna launches with $80M to support nasal spray for obstructive sleep apnea

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS